Compass Therapeutics Inc (CMPX) Stock Price, Quote & News

Company Profile

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 500 8099

Website: www.compasstherapeutics.com

Address:

80 Guest Street, Suite 601, Boston, United States

Congratulations May. 13 at 12:19 AM

$CMPX I’m thinking Friday. Just intuition. Bulls could gain full control by next week. Yall hang in there. So much optimism here!

2 · Reply

Heliosphere May. 12 at 10:06 PM

$CMPX $RHHBY or $AMGN should buy $CMPX Both have been in angiogenesis field and understand these pathways well. Avastin has already lost most of its patents now. Could replace Avastin in most oncology indications and new indications/combinations!

1 · Reply

Heliosphere May. 12 at 10:02 PM

$CMPX 2026 Stifel Virtual Targeted Oncology Forum Date: Wednesday, May 20, 2026 Time: 11:30 AM ET Webcast Link: https://event.summitcast.com/view/SScpdhHfwE8g9WsS8WcTax/QuhrzDf8Wdgui7i3FhuDb6

0 · Reply

Heliosphere May. 12 at 10:01 PM

$CMPX H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ Date: Tuesday, May 19, 2026 Time: 1:30 PM ET Webcast Link: https://journey.ct.events/view/bc55d2f9-d121-4f7d-8129-1f69f201bd7f

0 · Reply

Heliosphere May. 12 at 10:01 PM

$CMPX https://investors.compasstherapeutics.com/news-releases/news-release-details/compass-therapeutics-participate-upcoming-may-investor-events-0/

0 · Reply

Congratulations May. 12 at 5:30 PM

$CMPX will insiders have equity in their newly purchased open market shares by the close of business today?

0 · Reply

BlakeCanyon50 May. 12 at 4:46 PM

$CMPX My Only ✅ Stock Today.. The IRONY!

1 · Reply

Congratulations May. 12 at 3:52 PM

$CMPX I feel like a big move is coming

1 · Reply

SQUEAKSBANDIT May. 12 at 3:22 PM

$CMPX this name wants to go up, its just not in any particular hurry to do so

0 · Reply

BigLittleGambler May. 12 at 12:38 PM

$CMPX Well, I think the discussion with the FDA should be that a confirmatory trial is essentially unethical: a clinical trial would need to b performed while knowing we have an effective drug that save lives. My guess is really how many members of the committee will argue that the drug is not effective. I am really trying to understand where my reasoning fails, but the argument that the sickest population crossover AND live longer is probably the best argument against confounding.

1 · Reply

Compass Therapeutics to Participate in Upcoming May Investor Events

2026-05-05T12:13:40.000Z - 7 days ago

Compass Therapeutics reports Q1 EPS (10c), consensus (10c)

May 5, 2026, 7:30 AM EDT - 8 days ago

Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update

2026-04-28T11:13:42.000Z - 15 days ago

Compass Therapeutics price target lowered to $7 from $13 at Canaccord

2026-04-28T10:32:11.000Z - 15 days ago

Compass Therapeutics downgraded to Market Perform from Outperform at Raymond James

2026-04-27T19:20:47.000Z - 15 days ago

Compass Therapeutics price target lowered to $6 from $12 at Stifel

2026-04-27T18:05:41.000Z - 15 days ago

Compass Therapeutics selloff ‘an over-reaction,’ says Jefferies

2026-04-27T17:05:11.000Z - 15 days ago

Leerink says Compass data supports path forward for tovecimig in 2L BTC

Apr 27, 2026, 1:00 PM EDT - 15 days ago

Compass Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

2026-04-27T15:55:10.000Z - 15 days ago

H.C. Wainwright keeps Buy rating on Compass Therapeutics after data

Apr 27, 2026, 8:00 AM EDT - 15 days ago

Compass Therapeutics Transcript: Study update

2026-04-27T11:51:55.000Z - 16 days ago

Compass Therapeutics reports additional COMPANION-002 study results

Apr 27, 2026, 7:30 AM EDT - 16 days ago

Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

Apr 24, 2026, 4:00 PM EDT - 18 days ago

Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer

2026-03-05T12:38:02.000Z - 2 months ago

Compass Therapeutics reports Q4 EPS (9c), consensus (9c)

Mar 5, 2026, 7:30 AM EST - 2 months ago

Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update

2026-02-13T14:16:09.000Z - 3 months ago

Craig-Hallum bullish on Compass Therapeutics, initiates with a Buy

2026-02-13T13:15:26.000Z - 3 months ago

Compass Therapeutics initiated with a Buy at Craig-Hallum

2026-02-04T11:42:54.000Z - 3 months ago

Compass Therapeutics price target raised to $13 from $10 at Canaccord

Jan 14, 2026, 10:30 AM EST - 4 months ago

Compass Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

2026-01-06T13:36:59.000Z - 4 months ago

Compass Therapeutics provides corporate update

Jan 6, 2026, 8:00 AM EST - 4 months ago

Compass Therapeutics Provides Corporate Update

Jan 5, 2026, 4:30 PM EST - 4 months ago

Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-01-05T13:38:26.000Z - 4 months ago

Compass Therapeutics appoints Arjun Prasad as CCO, Cynthia Sirard as CMO

Jan 5, 2026, 8:00 AM EST - 4 months ago

Compass Therapeutics Announces Key Leadership Appointments

2026-01-05T11:01:21.000Z - 4 months ago

Compass Therapeutics initiated with an Outperform at William Blair

2025-12-30T21:10:54.000Z - 4 months ago

Compass Therapeutics files $400M mixed securities shelf

Dec 17, 2025, 7:30 AM EST - 5 months ago

Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference

Dec 4, 2025, 10:00 AM EST - 5 months ago

Compass Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 8:00 AM EST - 5 months ago

Compass Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 8:00 AM EST - 6 months ago

Compass Therapeutics to Participate in Upcoming December Investor Events

Nov 20, 2025, 7:30 AM EST - 6 months ago

Compass Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 4:00 PM EST - 6 months ago

Compass Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 3:30 PM EST - 6 months ago

Compass Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 5, 2025, 7:30 AM EST - 6 months ago

Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 4, 2025, 9:00 AM EST - 6 months ago

Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 3, 2025, 8:00 AM EST - 6 months ago

Compass Therapeutics to Participate in Upcoming November Investor Events

Sep 9, 2025, 5:35 PM EDT - 8 months ago

Compass Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 11:00 AM EDT - 8 months ago

Compass Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 2:10 PM EDT - 8 months ago

Compass Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 26, 2025, 8:00 AM EDT - 9 months ago

Compass Therapeutics to Participate in Upcoming September Investor Events

Aug 12, 2025, 10:28 PM EDT - 9 months ago

Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering

Aug 12, 2025, 4:01 PM EDT - 9 months ago

Compass Therapeutics Announces Proposed Public Offering

Aug 11, 2025, 8:00 AM EDT - 9 months ago

Compass Therapeutics Earnings Call Transcript: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 9 months ago

Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update

Aug 8, 2025, 4:01 PM EDT - 9 months ago

Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025

Jun 5, 2025, 11:05 AM EDT - 1 year ago

Compass Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 20, 2025, 11:30 AM EDT - 1 year ago

Compass Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 8, 2025, 1:30 PM EDT - 1 year ago

Compass Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update

$Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting$

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer

Apr 8, 2025, 3:00 PM EDT - 1 year ago

Compass Therapeutics Transcript: Stifel 2025 Virtual Targeted Oncology Forum

Apr 2, 2025, 4:05 PM EDT - 1 year ago

Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics Transcript: Study Update

Apr 1, 2025, 7:00 AM EDT - 1 year ago

Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

Mar 31, 2025, 4:05 PM EDT - 1 year ago

Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer

Feb 27, 2025, 8:00 AM EST - 1 year ago

Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update

Feb 6, 2025, 9:00 AM EST - 1 year ago

Compass Therapeutics Transcript: Guggenheim SMID Cap Biotech Conference

Dec 10, 2024, 8:00 AM EST - 1 year ago

Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer

Dec 4, 2024, 9:50 AM EST - 1 year ago

Compass Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 2, 2024, 8:00 AM EST - 1 year ago

Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 21, 2024, 9:00 AM EST - 1 year ago

Compass Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 13, 2024, 8:30 AM EST - 1 year ago

Compass Therapeutics to Participate in Upcoming Investor Events

Nov 12, 2024, 8:00 AM EST - 1 year ago

Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update

Nov 8, 2024, 10:05 AM EST - 1 year ago

Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 4, 2024, 10:31 AM EDT - 1 year ago

Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

Sep 9, 2024, 11:00 AM EDT - 1 year ago

Compass Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 7, 2024, 8:00 AM EDT - 1 year ago

Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference

May 28, 2024, 4:10 PM EDT - 2 years ago

Compass Therapeutics Announces CEO Transition

May 23, 2024, 5:05 PM EDT - 2 years ago

Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Mee

May 14, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 13, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update

Apr 12, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference

Apr 10, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics to Participate in the Stifel Targeted Oncology Days

Apr 9, 2024, 12:00 PM EDT - 2 years ago

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 21, 2024, 9:00 AM EDT - 2 years ago

Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update

Feb 29, 2024, 8:00 AM EST - 2 years ago

Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Nov 9, 2023, 7:30 AM EST - 2 years ago

Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Aug 3, 2023, 8:00 AM EDT - 3 years ago

Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Jun 22, 2023, 4:05 PM EDT - 3 years ago

Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes

May 4, 2023, 8:30 AM EDT - 3 years ago

Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

Apr 19, 2023, 8:30 AM EDT - 3 years ago

Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

Mar 28, 2023, 8:30 AM EDT - 3 years ago

Compass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology Symposium

Congratulations May. 13 at 12:19 AM

$CMPX I’m thinking Friday. Just intuition. Bulls could gain full control by next week. Yall hang in there. So much optimism here!

2 · Reply

Heliosphere May. 12 at 10:06 PM

1 · Reply

Heliosphere May. 12 at 10:02 PM

$CMPX 2026 Stifel Virtual Targeted Oncology Forum Date: Wednesday, May 20, 2026 Time: 11:30 AM ET Webcast Link: https://event.summitcast.com/view/SScpdhHfwE8g9WsS8WcTax/QuhrzDf8Wdgui7i3FhuDb6

0 · Reply

Heliosphere May. 12 at 10:01 PM

0 · Reply

Heliosphere May. 12 at 10:01 PM

$CMPX https://investors.compasstherapeutics.com/news-releases/news-release-details/compass-therapeutics-participate-upcoming-may-investor-events-0/

0 · Reply

Congratulations May. 12 at 5:30 PM

$CMPX will insiders have equity in their newly purchased open market shares by the close of business today?

0 · Reply

BlakeCanyon50 May. 12 at 4:46 PM

$CMPX My Only ✅ Stock Today.. The IRONY!

1 · Reply

Congratulations May. 12 at 3:52 PM

$CMPX I feel like a big move is coming

1 · Reply

SQUEAKSBANDIT May. 12 at 3:22 PM

$CMPX this name wants to go up, its just not in any particular hurry to do so

0 · Reply

BigLittleGambler May. 12 at 12:38 PM

1 · Reply

Arxidia May. 12 at 11:54 AM

$CMPX Well all that leads to a genuinely difficult strategic call to make soon; the direction of which will be decided upon the fda’s signals in the pre-BLA meeting, I guess. Should they (a) argue for full approval on totality of evidence (ORR + PFS + explainable (🤞🏼) OS confound, or (b) play it safe and seek accelerated approval on ORR alone? Full approval is higher risk but it obviously removes the confirmatory trial overhang entirely. Accelerated approval is arguably more achievable but keeps a dark shadow over the stock until that trial ends (hopefully) successfully.

0 · Reply

Heliosphere May. 12 at 1:08 AM

$CMPX https://www.cancernetwork.com/view/fda-grants-orphan-drug-designation-to-tovecimig-for-biliary-tract-cancer

0 · Reply

Heliosphere May. 12 at 12:49 AM

$CMPX https://www.biospace.com/press-releases/compass-therapeutics-reports-2026-first-quarter-financial-results-and-provides-corporate-update

1 · Reply

Heliosphere May. 11 at 9:15 PM

$CMPX https://dailynews.ascopubs.org/do/tovecimig-ctx-009-bispecific-antibody-targeting-dll4-and-vegf-a-perspectives-field

1 · Reply

Congratulations May. 11 at 7:26 PM

$CMPX I’ll be surprised if we see 1.81 on the bid again during market hours

0 · Reply

SQUEAKSBANDIT May. 11 at 7:19 PM

$CMPX just another day grindin it out won't be surprised we close under 1.80

0 · Reply

Congratulations May. 11 at 6:26 PM

Do you think $CMPX planned this bear trap from the beginning?

3 · Reply

Seeker1980 May. 11 at 6:20 PM

$CMPX The expert is here as well🤡

0 · Reply

Arxidia May. 11 at 6:08 PM

$CMPX behaving in the predicted channel so far. ASCO abstracts should be coming out on the 21st I believe- correct me if I’m wrong - so a chance for the company to remind everyone about its multi-asset pipeline. With things remaining constant we should be forming a base around $2 at that time. Not spectacular, by slowly-slowly catchie monkey given the circumstances. Eventual clear BLA path for tovecimig in the Summer should move the needle in a much more convincing way. Personally I have no doubt this will happen. I’m new on this, but the more I read I’m convinced ppl invested at pre crash levels will make their money back and then some. Good luck to us all fellas. I think we’ll be fine.

1 · Reply

BigBuddha May. 11 at 4:51 PM

$CMPX

0 · Reply

Congratulations May. 11 at 4:34 PM

$CMPX love this post:

0 · Reply

Homer_Simpson82 May. 11 at 4:12 PM

$CMPX see you under 1 soon. Easy

2 · Reply

Market Cap	329.56M
Revenue (ttm)	0.00
Net Income (ttm)	-66.49M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	5,212,900
Avg Vol	8,023,962
Day's Range	N/A - N/A
Shares Out	180.09M
Stochastic %K	57%
Beta	0.79
Analysts	Strong Sell
Price Target	$11.17